What is the role of febuxostat in the treatment of hyperuricemia?

Updated: Nov 03, 2020
  • Author: James W Lohr, MD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Febuxostat is an orally administered xanthine oxidase inhibitor that was approved by the US Food and Drug Administration (FDA) in 2009 for the long-term treatment of hyperuricemia in patients with gout. In the CONFIRMS trial, a 6-month study that compared febuxostat and allopurinol in 2269 subjects with gout and serum urate levels ≥8.0 mg/dL, febuxostat 80 mg daily proved superior to allopurinol in lowering uric acid levels in patients with normal renal function, and febuxostat 40 mg daily was equivalent to allopurinol in such patients. In patients with mild-to-moderate renal impairment, febuxostat at any dose was superior to allopurinol in lowering uric acid levels. [33]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!